Company news
Ionis Pharmaceuticals, Inc. news in 2019
Ionis Pharmaceuticals, Inc.'s news releases, calls and decks from 2019, newest first.
Ionis Pharmaceuticals announces private placement of $507.5 million principal amount of 0.125% convertible senior notes due 2024
December 11, 2019
Akcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with Polyneuropathy Driven by Hereditary TTR Amyloidosis
November 24, 2019
Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for Investigative Antisense Therapy AKCEA-ANGPTL3-L(Rx)
November 18, 2019
Ionis Pharmaceuticals to hold third quarter 2019 financial results webcast
October 21, 2019
Ionis' Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results
October 8, 2019
Ionis licenses hepatitis B program to GSK
August 26, 2019
Ionis Reports Second Quarter 2019 Financial Results
August 6, 2019
Ionis Pharmaceuticals to hold second quarter 2019 financial results webcast
July 29, 2019
Ionis announces appointment of Joan E. Herman to its board of directors
June 11, 2019
Ionis launches new corporate brand that reflects company's industry-leading innovation and unique culture of saying "yes" to patients
May 5, 2019